A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)

Benilde Cosmi, Massimo Filippini, Daniele Tonti, Giampiero Avruscio, Angelo Ghirarduzzi, Eugenio Bucherini, Giuseppe Camporese, Davide Imberti, Gualtiero Palareti, Elisabetta Favaretto, Fausto Campana, Sonia Ragazzo, Fabio Ceccato, Stefania Rondinello, Maria Rosaria Veropalumbo, Matteo Iotti, Maria Andreozzi Giuseppe, Fabio Verlato, Davide Imberti, Vincenzo PriscoRosaria Greco, Leonardo Aluigi, Adriana Visoná, Beniamino Zalunardo, Zotta Laura, Tonello Diego, Carmelo Amico, Paolo Benin, Vincenzo Vella, Gianfranco Boccoli, Leonardo Chiodi, Daniele Aloisi, Lucia Angeloni, Demetrio Postacchini, Guido Cruciani, Ilenia Macchiati, Andrea Grossi, Saverino La Placa, Carlo Renzi, Dimitrios Kontothanassis

Research output: Contribution to journalArticlepeer-review


Background: Optimal doses and duration of low-molecular-weight heparin (LMWH) for the treatment of superficial vein thrombosis (SVT) are still uncertain. Objectives: To compare the efficacy and safety of different doses and durations of LMWH parnaparin for symptomatic lower limb SVT. Patients and methods: Outpatients with at least a 4-cm-long SVT of long or short saphenous veins or their collaterals were randomized to receive parnaparin either 8500UIonce daily (o.d.) for 10days followed by placebo for 20days (group A) or 8500UIo.d. for 10days followed by 6400UIonce daily (o.d.) for 20days (group B) or 4250UIo.d. for 30days (group C) in a double-blind fashion in 16 clinics. Primary outcome was the composite of symptomatic and asymptomatic deep vein thrombosis (DVT), symptomatic pulmonary embolism (PE) and relapse and/or symptomatic or asymptomatic SVT recurrence in the first 33days with 60days follow-up. Results: Among 664 patients, primary outcome occurred in 33/212 (15.6%), 4/219 (1.8%) and 16/217 (7.3%) subjects in groups A, B and C, respectively (B vs. A: absolute risk reduction [ARR]: 13.7%, 95% confidence intervals [CI]: 8-18.9 P

Original languageEnglish
Pages (from-to)1026-1035
Number of pages10
JournalJournal of Thrombosis and Haemostasis
Issue number6
Publication statusPublished - Jun 2012


  • Deep vein thrombosis
  • Low molecular weight heparin
  • Pulmonary embolism
  • Randomized clinical trial
  • Superficial vein thrombosis
  • Venous thromboembolism

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum)'. Together they form a unique fingerprint.

Cite this